The benefit-harm balance of initiating Glucagon-like Peptide-1 (GLP-1) receptor agonists (RAs) versus a placebo intervention.
GLP-1 receptor agonists effective for weight loss in obesity without diabetes
- Post author:
- Post published:May 29, 2024
- Post category:uncategorized